These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. Hoppe UC; Brandt MC; Wachter R; Beige J; Rump LC; Kroon AA; Cates AW; Lovett EG; Haller H J Am Soc Hypertens; 2012; 6(4):270-6. PubMed ID: 22694986 [TBL] [Abstract][Full Text] [Related]
8. Anesthetic management for implantation of a treatment device: the Rheos Baroreflex Hypertensive Therapy System. Thai NN AANA J; 2012 Feb; 80(1):18-24. PubMed ID: 22474800 [TBL] [Abstract][Full Text] [Related]
9. Rheos Baroreflex Hypertension Therapy System to treat resistant hypertension. Scheffers IJ; Kroon AA; Tordoir JH; de Leeuw PW Expert Rev Med Devices; 2008 Jan; 5(1):33-9. PubMed ID: 18095894 [TBL] [Abstract][Full Text] [Related]
10. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension. Wallbach M; Lehnig LY; Schroer C; Lüders S; Böhning E; Müller GA; Wachter R; Koziolek MJ Hypertension; 2016 Apr; 67(4):701-9. PubMed ID: 26902491 [TBL] [Abstract][Full Text] [Related]
11. Rheos: an implantable carotid sinus stimulation device for the nonpharmacologic treatment of resistant hypertension. Ng MM; Sica DA; Frishman WH Cardiol Rev; 2011; 19(2):52-7. PubMed ID: 21285662 [TBL] [Abstract][Full Text] [Related]
12. Baroreflex activation therapy lowers arterial pressure without apparent stimulation of the carotid bodies. Alnima T; Goedhart EJ; Seelen R; van der Grinten CP; de Leeuw PW; Kroon AA Hypertension; 2015 Jun; 65(6):1217-22. PubMed ID: 25941348 [TBL] [Abstract][Full Text] [Related]
13. Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension. Alnima T; de Leeuw PW; Tan FE; Kroon AA; Hypertension; 2013 Jun; 61(6):1334-9. PubMed ID: 23589562 [TBL] [Abstract][Full Text] [Related]
14. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. Bisognano JD; Kaufman CL; Bach DS; Lovett EG; de Leeuw P; J Am Coll Cardiol; 2011 Apr; 57(17):1787-8. PubMed ID: 21511116 [No Abstract] [Full Text] [Related]
15. Baroreceptor stimulation for resistant hypertension: first implantation in France and literature review. Courand PY; Feugier P; Workineh S; Harbaoui B; Bricca G; Lantelme P Arch Cardiovasc Dis; 2014 Dec; 107(12):690-6. PubMed ID: 25445751 [TBL] [Abstract][Full Text] [Related]
16. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. de Leeuw PW; Bisognano JD; Bakris GL; Nadim MK; Haller H; Kroon AA; Hypertension; 2017 May; 69(5):836-843. PubMed ID: 28320856 [TBL] [Abstract][Full Text] [Related]
17. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Wustmann K; Kucera JP; Scheffers I; Mohaupt M; Kroon AA; de Leeuw PW; Schmidli J; Allemann Y; Delacrétaz E Hypertension; 2009 Sep; 54(3):530-6. PubMed ID: 19620513 [TBL] [Abstract][Full Text] [Related]
18. Baroreflex activation for the treatment of hypertension: principles and practice. Sica DA; Lohmeier TE Expert Rev Med Devices; 2006 Sep; 3(5):595-601. PubMed ID: 17064245 [TBL] [Abstract][Full Text] [Related]
19. Resistant hypertension: baroreflex stimulation as a new tool. Menne J; Jordan J; Linnenweber-Held S; Haller H Nephrol Dial Transplant; 2013 Feb; 28(2):288-95. PubMed ID: 23223217 [TBL] [Abstract][Full Text] [Related]